^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | SCT200 (EGFR antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell cancer.
Published date:
05/19/2021
Excerpt:
Improved median PFS (3.4 vs. 1.4 months, P = 0.006) and OS (8.0 vs. 4.2 months, P = 0.027) were associated with TP53 mutation abundance of < 10%....SCT200 monotherapy as second- or further-line for advanced ESCC showed favorable efficacy, with an acceptable safety profile. TP53 mutation abundance might serve as potential predictive biomarkers.
Trial ID:
